Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(2.63)
# 2,218
Out of 5,049 analysts
52
Total ratings
30.61%
Success rate
1.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVAX Novavax | Initiates: Overweight | $18 | $7.51 | +139.68% | 1 | Oct 24, 2025 | |
| ALEC Alector | Downgrades: Neutral | n/a | $1.32 | - | 6 | Oct 22, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Neutral | n/a | $1.81 | - | 5 | Jul 7, 2025 | |
| DRUG Bright Minds Biosciences | Assumes: Overweight | n/a | $51.29 | - | 1 | Jul 2, 2025 | |
| VERA Vera Therapeutics | Maintains: Overweight | $107 → $100 | $24.35 | +310.68% | 8 | May 7, 2025 | |
| VYGR Voyager Therapeutics | Reiterates: Overweight | n/a | $4.16 | - | 2 | Mar 12, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Overweight | n/a | $8.93 | - | 6 | Mar 7, 2025 | |
| PLRX Pliant Therapeutics | Reinstates: Neutral | n/a | $1.61 | - | 5 | Mar 4, 2025 | |
| KALV KalVista Pharmaceuticals | Reiterates: Overweight | n/a | $10.76 | - | 1 | Dec 9, 2024 | |
| ANNX Annexon | Reiterates: Overweight | n/a | $3.08 | - | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.91 | - | 1 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $33.18 | - | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $8.90 | -43.82% | 3 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.94 | +570.10% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $15.41 | -48.09% | 1 | Mar 20, 2023 |
Novavax
Oct 24, 2025
Initiates: Overweight
Price Target: $18
Current: $7.51
Upside: +139.68%
Alector
Oct 22, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.32
Upside: -
Jasper Therapeutics
Jul 7, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.81
Upside: -
Bright Minds Biosciences
Jul 2, 2025
Assumes: Overweight
Price Target: n/a
Current: $51.29
Upside: -
Vera Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $107 → $100
Current: $24.35
Upside: +310.68%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.16
Upside: -
Arcturus Therapeutics Holdings
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $8.93
Upside: -
Pliant Therapeutics
Mar 4, 2025
Reinstates: Neutral
Price Target: n/a
Current: $1.61
Upside: -
KalVista Pharmaceuticals
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.76
Upside: -
Annexon
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.08
Upside: -
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.91
Upside: -
Jun 27, 2024
Initiates: Overweight
Price Target: n/a
Current: $33.18
Upside: -
Sep 19, 2023
Reiterates: Overweight
Price Target: $5
Current: $8.90
Upside: -43.82%
Jul 17, 2023
Reiterates: Overweight
Price Target: $13
Current: $1.94
Upside: +570.10%
Mar 20, 2023
Reiterates: Overweight
Price Target: $8
Current: $15.41
Upside: -48.09%